We are live on ! Find out more
GH icon

Guardant Health

Positive
Neutral
Negative
Sentiment 3-Months
Positive 34.4%
Neutral 59.4%
Negative 6.3%

Positive
Seeking Alpha
2 days ago
Artisan Mid Cap Fund Q2 2026 Performance Review
Artisan Mid Cap Fund portfolio generated strong absolute returns and outpaced the Russell Midcap® Growth Index. Within IT, several semiconductor holdings produced exceptional returns, with multiple positions rising more than 100% during the period. During the quarter, we initiated new positions in Entegris, Modine Manufacturing and C.H. Robinson Worldwide.
Artisan Mid Cap Fund Q2 2026 Performance Review
Neutral
Business Wire
8 days ago
Guardant Health to Report Second Quarter 2026 Financial Results on July 30, 2026
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2026 after market close on Thursday, July 30, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will.
Guardant Health to Report Second Quarter 2026 Financial Results on July 30, 2026
Positive
Investors Business Daily
8 days ago
The Surprising Reason Guardant Health, A Top 3% Stock, Soared To A Five-Year High
Guardant Health stock jumped Thursday after key competitor, Freenome, unveiled study results for its colon cancer blood test.
The Surprising Reason Guardant Health, A Top 3% Stock, Soared To A Five-Year High
Neutral
Business Wire
16 days ago
UnitedHealth Group Now Covers Guardant Health's Shield Blood Test for Colorectal Cancer Screening
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) is now covered for eligible UnitedHealth Group (UHG) members1, making it the first major commercial insurer to provide coverage for adults 45 or older amid rising CRC rates for adults under 652 and mortality for younger adults as the leading cause of cancer death for those under 50.3 Shield is the first and onl.
UnitedHealth Group Now Covers Guardant Health's Shield Blood Test for Colorectal Cancer Screening
Positive
Barrons
29 days ago
Living Longer Is Big Business. These Stocks Will Benefit.
TD Cowen analysts estimate that the total addressable market for longevity healthcare exceeds $250 billion.
Living Longer Is Big Business. These Stocks Will Benefit.
Neutral
Newsfile Corp
1 month ago
Gamehost Receives Final Court Order Authorizing Sale to Pure Casino Entertainment
Not intended for distribution to U.S. newswire services or for dissemination in the U.S. Red Deer, Alberta--(Newsfile Corp. - June 15, 2026) - Gamehost Inc. (TSX: GH) ("Gamehost") announced that the Court of King's Bench of Alberta has granted the final order authorizing Gamehost to proceed with its previously announced transaction with Pure Casino Entertainment Limited Partnership ("Pure") pursuant to which a subsidiary of Pure will acquire all of the outstanding common shares of Gamehost (the "Gamehost Shares") for $13.65 in cash per share (the "Transaction"). The Transaction was approved at a special meeting of the shareholders of Gamehost (the "Gamehost Shareholders") held on June 11, 2026.
Gamehost Receives Final Court Order Authorizing Sale to Pure Casino Entertainment
Neutral
Newsfile Corp
1 month ago
Gamehost Shareholders Approve Sale to Pure Casino Entertainment
Red Deer, Alberta--(Newsfile Corp. - June 12, 2026) - Gamehost Inc. (TSX: GH) ("Gamehost") announced that its shareholders (the "Gamehost Shareholders") have approved its previously announced transaction with Pure Casino Entertainment Limited Partnership ("Pure") pursuant to which a subsidiary of Pure will acquire all of the outstanding common shares of Gamehost (the "Gamehost Shares") for $13.65 in cash per share (the "Transaction"). The Transaction was approved at a special meeting of the Gamehost Shareholders held on June 11, 2026 (the "Meeting").
Gamehost Shareholders Approve Sale to Pure Casino Entertainment
Neutral
Business Wire
1 month ago
Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim's HERNEXEOS®
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic (CDx) for Boehringer Ingelheim's HERNEXEOS® (zongertinib tablets), the first targeted therapy for adults with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) as an initial treatment option. The approval enables Guardant360 CDx, a liquid biopsy test tha.
Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim's HERNEXEOS®
Positive
Investors Business Daily
1 month ago
Here's Why This Colon Cancer Testing Biotech Is A Mutual Fund Favorite
This biotech has a one-of-a-kind colon cancer blood test. Shares broke out of a base on recent news.
Here's Why This Colon Cancer Testing Biotech Is A Mutual Fund Favorite
Neutral
Business Wire
1 month ago
Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present 38 abstracts, as well as one oral presentation in partnership with Pfizer, showcasing advances in methylation-based tumor classification and liquid biopsy technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois taking place May 29 – June 2, 2026. Key data that will be prese.
Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting